Disease Info Card

Persistant Generalized Lymphadenopathy

Information about Persistant Generalized Lymphadenopathy: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Persistant Generalized Lymphadenopathy

Most recent studies have shown that Persistant Generalized Lymphadenopathy shares some biological mechanisms with acquired-immunodeficiency-syndrome, aids-related-complex, generalized-enlarged-lymph-nodes, hemorrhage, hiv-infections, hyperplasia, immunologic-deficiency-syndromes, infective-disorder, inflammation, kaposi-sarcoma, lymphatic-diseases, lymphoma, malignant-neoplasms, malignant-paraganglionic-neoplasm, neoplasms, opportunistic-infections, sarcoma, thrombosis, tuberculosis, virus-diseases.

Among the many pathways, these few ones have gauged particular interests from scientists studying Persistant Generalized Lymphadenopathy, and have been seen in publications frequently: Angiogenesis, Blood Coagulation, Cell Activation, Cell Migration, Cell Proliferation, Coagulation, Fibrinolysis, Hemostasis, Hypersensitivity, Immune Response, Inflammatory Response, Localization, Pathogenesis, Plasminogen Activation, Proteolysis, Regeneration, Secretion, Tissue Remodeling, Virulence, Wound Healing

Quite a number of genes have been found to play important roles in Persistant Generalized Lymphadenopathy, such as ALB, ARC, CD4, F2, FN1, IL2, LPA, NOL3, PLAT, PLAU, PLAUR, PLG, POMC, PRAP1, SDHD, SERPINB2, SERPINC1, SERPINE1. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.